Tanaka Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Tanaka Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.81M	Sell	113,418 -1,000	-0.9%	-$23.8K	4.69%	9
2025 Q4	$2.67M	Hold	114,418	–	–	4.87%	7
2025 Q3	$2.25M	Buy	+114,418	New	+$2.35M	4.06%	10
2025 Q1	$3.68M	Sell	151,893 -1,398	-0.9%	-$31.5K	8.77%	3
2024 Q4	$3.2M	Hold	153,291	–	–	7.31%	5
2024 Q3	$3.05M	Sell	153,291 -100	-0.1%	-$1.85K	7.05%	5
2024 Q2	$2.38M	Hold	153,391	–	–	5.62%	6
2024 Q1	$2.44M	Sell	153,391 -1,040	-0.7%	-$15.7K	6.02%	5
2023 Q4	$2.6M	Sell	154,431 -5,360	-3%	-$73.3K	6.35%	4
2023 Q3	$1.87M	Hold	159,791	–	–	5.34%	7
2023 Q2	$2.15M	Buy	159,791 +11,510	+8%	+$166K	5.81%	5
2023 Q1	$2.46M	Hold	148,281	–	–	7.14%	3
2022 Q4	$2.76M	Hold	148,281	–	–	8.75%	4
2022 Q3	$1.9M	Sell	148,281 -48,970	-25%	-$580K	5.68%	5
2022 Q2	$1.38M	Sell	197,251 -10,938	-5%	-$80.2K	4.5%	9
2022 Q1	$1.73M	Sell	208,189 -5,420	-3%	-$38.3K	3.49%	9
2021 Q4	$1.45M	Buy	213,609 +10,530	+5%	+$69.2K	2.75%	9
2021 Q3	$1.08M	Buy	203,079 +30,000	+17%	+$164K	1.53%	12
2021 Q2	$995K	Sell	173,079 -51,695	-23%	-$267K	1.34%	14
2021 Q1	$1.04M	Sell	224,774 -500	-0.2%	-$1.99K	1.31%	14
2020 Q4	$752K	Sell	225,274 -26,925	-11%	-$90.5K	1.67%	14
2020 Q3	$749K	Sell	252,199 -31,295	-11%	-$122K	2.35%	13
2020 Q2	$1.31M	Buy	283,494 +5,720	+2%	+$25.7K	4.06%	5
2020 Q1	$1.07M	Sell	277,774 -4,650	-2%	-$19.1K	4.68%	4
2019 Q4	$1.06M	Sell	282,424 -910	-0.3%	-$4.26K	3.36%	8
2019 Q3	$1.5M	Buy	283,334 +57,750	+26%	+$308K	4.86%	6
2019 Q2	$866K	Sell	225,584 -8,210	-4%	-$35.5K	2.65%	17
2019 Q1	$1.19M	Sell	233,794 -16,889	-7%	-$49.6K	3.59%	9
2018 Q4	$481K	Hold	250,683	–	–	1.53%	19
2018 Q3	$948K	Hold	250,683	–	–	2.2%	18
2018 Q2	$782K	Sell	250,683 -5,910	-2%	-$17.9K	1.87%	18
2018 Q1	$613K	Hold	256,593	–	–	1.47%	21
2017 Q4	$1M	Buy	256,593 +15,515	+6%	+$51.3K	2.29%	13
2017 Q3	$608K	Hold	241,078	–	–	1.36%	24
2017 Q2	$665K	Sell	241,078 -675	-0.3%	-$1.41K	1.52%	23
2017 Q1	$416K	Sell	241,753 -348,130	-59%	-$443K	0.92%	28
2016 Q4	$590K	Sell	589,883 -91,730	-13%	-$105K	1.38%	25
2016 Q3	$712K	Hold	681,613	–	–	1.71%	20
2016 Q2	$464K	Hold	681,613	–	–	1.19%	24
2016 Q1	$764K	Buy	681,613 +569,920	+510%	+$884K	1.72%	22
2015 Q4	$237K	Hold	111,693	–	–	0.51%	35
2015 Q3	$335K	Hold	111,693	–	–	0.85%	26
2015 Q2	$462K	Hold	111,693	–	–	1.15%	26
2015 Q1	$438K	Sell	111,693 -26,800	-19%	-$96.6K	1.21%	23
2014 Q4	$355K	Sell	138,493 -9,500	-6%	-$26.1K	1.06%	26
2014 Q3	$414K	Hold	147,993	–	–	1.21%	24
2014 Q2	$338K	Hold	147,993	–	–	0.89%	27
2014 Q1	$298K	Hold	147,993	–	–	0.91%	27
2013 Q4	$251K	Hold	147,993	–	–	0.74%	28
2013 Q3	$414K	Hold	147,993	–	–	1.42%	23
2013 Q2	$107K	Buy	+147,993	New	+$118K	0.38%	34

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Tanaka Capital Management's CPRX Position: Q1 2026 in Review

Tanaka Capital Management reduced its Catalyst Pharmaceutical (CPRX) stake by 0.87% in Q1 2026, selling an estimated $23.8K and leaving 113,418 shares worth $2.81M. The position accounts for 4.69% of the portfolio, ranked #9.

Tanaka Capital Management first reported a position in CPRX in Q2 2013 and has held it in 51 quarters since. The position peaked at $3.68M in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Tanaka Capital Management held 113,418 shares of Catalyst Pharmaceutical worth $2.81M as of Q1 2026.
Tanaka Capital Management sold 1,000 Catalyst Pharmaceutical shares in Q1 2026, an estimated $23.8K.
Catalyst Pharmaceutical made up 4.69% of Tanaka Capital Management's portfolio in Q1 2026, its #9 holding.
Tanaka Capital Management first reported a position in Catalyst Pharmaceutical in Q2 2013 and has held it in 51 quarters since.
Tanaka Capital Management's Catalyst Pharmaceutical position peaked at $3.68M in Q1 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Tanaka Capital Management's 13F filing for Q1 2026, filed 18 May 2026.